Farallon Capital Management’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
Other funds holding PACB
Farallon Capital Management's PACB Position: Q3 2026 in Review
Farallon Capital Management held its Pacific Biosciences (PACB) position steady in Q3 2026 at 14,200 shares worth $33.7K. The position accounts for ﹤0.01% of the portfolio, ranked #112.
Farallon Capital Management first reported a position in PACB in Q4 2019 and has held it in 25 quarters since. The position peaked at $111M in Q2 2023. 205 funds tracked by Wall St. Rank hold PACB as of Q3 2026.
- Farallon Capital Management held 14,200 shares of Pacific Biosciences worth $33.7K as of Q3 2026.
- Farallon Capital Management left its Pacific Biosciences share count unchanged in Q3 2026.
- Pacific Biosciences made up ﹤0.01% of Farallon Capital Management's portfolio in Q3 2026, its #112 holding.
- Farallon Capital Management first reported a position in Pacific Biosciences in Q4 2019 and has held it in 25 quarters since.
- Farallon Capital Management's Pacific Biosciences position peaked at $111M in Q2 2023.
- 205 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2026.
Based on Farallon Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.